Company intelligence / Profile preview

Dormotech

Ownership: Private
Development stage: Commercial

Overview

Dormotech has developed FDA-cleared, AI-powered wireless diagnostic platforms—DormoVision X™ and Vlab—for comprehensive at-home and in-lab polysomnography. Clinical validation studies show 96.6% agreement with gold-standard PSG across key metrics such as AHI, EEG, EOG, EMG, and oxygen saturation. The devices are self-applied, comfortable for multi-night use including pediatric populations, enable real-time remote monitoring by clinicians, and have demonstrated zero reported adverse events in trials.

Therapeutic areas: PulmonologyNeurology
Modalities: DeviceNon-pharmacological therapy
Industry: Physiological Monitoring

Partnerships

Beta site agreements with two major sleep labs as of late 2022

Beyond the preview

Go deeper on Dormotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dormotech.

Explore the full profile